Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00306995 |
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity. If such virus is pathogenic to human and demonstrates the ability to transmit from person to person, the result is a global outbreak of disease that affects a high percentage of individuals in a short period of time and is likely to cause substantially increased mortality and morbidity in all countries of the world. Recently, purely avian influenza viruses, including the H5N1, H9N2 and H7N7 subtypes, have been directly transmitted to humans, raising concern over the possibility of a new influenza pandemic among the world's immunologically naive populations. In order to face this kind of situation, a pandemic influenza vaccine has to be developed.
Condition | Intervention | Phase |
---|---|---|
Influenza |
Biological: 3 adjuvanted pandemic influenza candidate vaccines + 4 non-adjuvanted pandemic influenza candidate vaccines |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Parallel Assignment, Safety Study |
Official Title: | A Phase III, Open, Randomized, Multicenter, Comparative Vaccination Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of a Monovalent Candidate Pandemic Influenza A Vaccine in Individuals Over 60 Years of Age |
Estimated Enrollment: | 385 |
Study Start Date: | May 2005 |
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Germany, Brandenburg | |
GSK Investigational Site | |
Finsterwalde, Brandenburg, Germany, 03238 | |
GSK Investigational Site | |
Ketzin, Brandenburg, Germany, 14669 | |
Germany, Niedersachsen | |
GSK Investigational Site | |
Tostedt, Niedersachsen, Germany, 21255 | |
Germany, Sachsen | |
GSK Investigational Site | |
Geringswalde, Sachsen, Germany, 09326 | |
GSK Investigational Site | |
Dresden, Sachsen, Germany, 01219 | |
GSK Investigational Site | |
Schmiedeberg, Sachsen, Germany, 01762 | |
GSK Investigational Site | |
Dresden, Sachsen, Germany, 01307 | |
Germany, Schleswig-Holstein | |
GSK Investigational Site | |
Bad Bramstedt, Schleswig-Holstein, Germany, 24576 | |
GSK Investigational Site | |
Bad Segeberg, Schleswig-Holstein, Germany, 23795 | |
GSK Investigational Site | |
Elmshorn, Schleswig-Holstein, Germany, 25335 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 102499 |
Study First Received: | February 16, 2006 |
Last Updated: | May 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00306995 History of Changes |
Health Authority: | Germany: Paul-Ehrlich-Institut |
prophylaxis of pandemic influenza |
Virus Diseases Respiratory Tract Diseases Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections |
Virus Diseases RNA Virus Infections Respiratory Tract Diseases |
Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections |